As a R&D oriented, bio-technology company with intensive experiences and advanced technologies, MEDINET has been making strenuous efforts to enrich cancer patients’ accessibility toward the Immuno-Cell Therapy.

In fiscal year 2009 (FY2009; October 2009 - September 2010), MEDINET has focused its business activities on expansion of the Immuno-Cell Therapy market in order to maximize its core service, Immuno-Cell Therapy Total Support Service (The service consists of necessary facilities, materials and reagents, qualified cell engineers, and quality-assurance expertise.). As a result of such intensive activities, MEDINET achieved record revenues and profits in FY2009 and accomplished its FY2009’s goal of continuous　profitability.

For successful leap in future business development, we will leverage our strengths to fulfill our missions, responding to demand for Immuno-Cell Therapy outside of Japan as well as co-developing new and novel treatment technologies for other refractory diseases besides cancer.

We are grateful for your support, and we will prove ourselves worthy of your trust.